APA (7th ed.) Citation

Shorr, A. F., Jones, M. E., Friedmann, S., Ionescu, D., Saulay, M., Smart, J. I., & Engelhardt, M. (2025). Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Shorr, Andrew F., Mark E. Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I. Smart, and Marc Engelhardt. Ceftobiprole Versus Ceftriaxone ± Linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a Randomized, Phase 3 Study Using 2020 FDA Guidance. Public Library of Science (PLoS), 2025.

MLA (9th ed.) Citation

Shorr, Andrew F., et al. Ceftobiprole Versus Ceftriaxone ± Linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a Randomized, Phase 3 Study Using 2020 FDA Guidance. Public Library of Science (PLoS), 2025.